1,9-Dibenzyl-2-(1-ethoxy-vinyl)-1,9-dihydro-purin-6-one | 883977-30-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1,9-Dibenzyl-2-(1-ethoxy-vinyl)-1,9-dihydro-purin-6-one
• 英文别名: 1,9-dibenzyl-2-(1-ethoxyethenyl)purin-6-one
• CAS: 883977-30-8
• 化学式: C₂₃H₂₂N₄O₂
• 分子量: 386.453
• InChiKey: KBYHKCLYAZYGIL-UHFFFAOYSA-N

物化性质

• 沸点：
  607.5±65.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  29.0
• 可旋转键数：
  7.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  61.94
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  1,9-Dibenzyl-2-(1-ethoxy-vinyl)-1,9-dihydro-purin-6-one 在 盐酸 、 sodium hydroxide 、 sodium t-butanolate 作用下， 以 甲醇 、 丙酮 为溶剂， 生成
  参考文献：
  名称：

  β-Diketo acids with purine nucleobase scaffolds: Novel, selective inhibitors of the strand transfer step of HIV integrase

  摘要：

  The HIV pol gene encodes three viral enzymes that are required for its replication. While drug discovery involving the viral targets, reverse transcriptase and protease, has resulted in useful therapeutic agents, such efforts on HIV integrase have not produced a single FDA-approved drug. In the work focused on the discovery of inhibitors of HIV integrase, we have synthesized new beta-diketo acids with purine nucleobase scaffolds that are potent inhibitors of the strand transfer steps of wild-type HIV-1 integrase. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.093
• 作为产物：
  描述：

  N-2-乙酰鸟嘌呤 在 palladium on activated charcoal bis-triphenylphosphine-palladium(II) chloride 、 ammonium hydroxide 、 sodium hydroxide 、 亚硝酸特丁酯 、 二碘甲烷 、 甲酸铵 、 sodium hydride 、 三氯氧磷 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 1,9-Dibenzyl-2-(1-ethoxy-vinyl)-1,9-dihydro-purin-6-one
  参考文献：
  名称：

  β-Diketo acids with purine nucleobase scaffolds: Novel, selective inhibitors of the strand transfer step of HIV integrase

  摘要：

  The HIV pol gene encodes three viral enzymes that are required for its replication. While drug discovery involving the viral targets, reverse transcriptase and protease, has resulted in useful therapeutic agents, such efforts on HIV integrase have not produced a single FDA-approved drug. In the work focused on the discovery of inhibitors of HIV integrase, we have synthesized new beta-diketo acids with purine nucleobase scaffolds that are potent inhibitors of the strand transfer steps of wild-type HIV-1 integrase. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.093